急性冠脉综合征PCI术后早期停用阿司匹林
该多中心、开放标签、随机试验在巴西纳入3410例成功PCI的ACS患者,住院前4天内按1:1随机分为停用阿司匹林接受强效P2Y12抑制剂单药治疗(替格瑞洛或普拉格雷)组(1712例)或双联抗血小板治疗(阿司匹林联合强效P2Y12抑制剂)组(1698例),疗程12个月。12个月时,单药组死亡、心肌梗死、卒中或紧急靶血管血运重建复合终点发生119例(Kaplan-Meier估计7.0%),双联组93例(5.5%),绝对风险差1.47个百分点(95%CI -0.16至3.10),非劣效检验P=0.11,未达到非劣效。大出血或临床相关非大出血单药组33例(2.0%)vs 双联组82例(4.9%),绝对风险差-2.97个百分点(95%CI -4.20至-1.73)。支架血栓单药组12例 vs 双联组4例。
要点
- ACS成功PCI后4天内停用阿司匹林、改为替格瑞洛或普拉格雷单药治疗12个月,死亡/心梗/卒中/紧急靶血管血运重建复合终点7.0% vs 双联组5.5%,绝对风险差1.47个百分点(95%CI -0.16至3.10),非劣效检验P=0.11,未达到非劣效。
- 大出血或临床相关非大出血单药组2.0% vs 双联组4.9%,绝对风险差-2.97个百分点(95%CI -4.20至-1.73),单药组出血更少。
- 支架血栓单药组12例 vs 双联组4例。
- 该试验为多中心、开放标签、随机、非劣效设计,非劣效界值2.5个百分点,主要终点未达到非劣效。
适用人群与场景
- 巴西多中心纳入的急性冠脉综合征患者,均已成功接受经皮冠状动脉介入治疗(PCI)。
- 随机分组在住院前4天内进行。
处置流程与药物剂量
- 单药组:停用阿司匹林,接受强效P2Y12抑制剂单药治疗(替格瑞洛或普拉格雷),疗程12个月。
- 双联抗血小板治疗组:阿司匹林联合强效P2Y12抑制剂,疗程12个月。
研究设计与关键结果
- 多中心、开放标签、随机试验,意向性治疗人群3410例(单药组1712例,双联组1698例)。
- 12个月死亡、心肌梗死、卒中或紧急靶血管血运重建:单药组119例(Kaplan-Meier估计7.0%)vs 双联组93例(5.5%),绝对风险差1.47个百分点(95%CI -0.16至3.10),非劣效检验P=0.11,未达到非劣效(非劣效界值2.5个百分点)。
- 大出血或临床相关非大出血:单药组33例(2.0%)vs 双联组82例(4.9%),绝对风险差-2.97个百分点(95%CI -4.20至-1.73)。
- 支架血栓:单药组12例 vs 双联组4例。
证据类型、等级与局限
- 证据类型:多中心、开放标签、随机对照试验(非劣效设计,非劣效界值2.5个百分点)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于ACS成功PCI后患者,早期停用阿司匹林改为强效P2Y12抑制剂单药治疗可使大出血或临床相关非大出血从4.9%降至2.0%,但死亡或缺血事件复合终点未达到非劣效(7.0% vs 5.5%),支架血栓单药组12例 vs 双联组4例。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Whether potent P2Y12 inhibitor monotherapy without aspirin initiated shortly after successful percutaneous coronary intervention (PCI) is effective and safe for patients with acute coronary syndromes is unclear.
METHODS: We conducted a multicenter, open-label, randomized trial in Brazil involving patients with acute coronary syndromes who had undergone successful PCI. Patients were assigned in a 1:1 ratio within the first 4 days of hospitalization to stop treatment with aspirin and receive potent P2Y12 inhibitor monotherapy (ticagrelor or prasugrel) or to receive dual antiplatelet therapy (aspirin and a potent P2Y12 inhibitor) for 12 months. The two ranked primary outcomes, assessed through 12 months, were a composite of death from any cause, myocardial infarction, stroke, or urgent target-vessel revascularization (tested for noninferiority, with a noninferiority margin of 2.5 percentage points) and major or clinically relevant nonmajor bleeding (tested for superiority).
RESULTS: A total of 3410 patients were included in the intention-to-treat population (1712 in the monotherapy group and 1698 in the dual antiplatelet therapy group). At 12 months, death from any cause, myocardial infarction, stroke, or urgent revascularization had occurred in 119 patients (Kaplan-Meier estimate, 7.0%) in the monotherapy group and in 93 patients (Kaplan-Meier estimate, 5.5%) in the dual antiplatelet therapy group (absolute risk difference, 1.47 percentage points; 95% confidence interval [CI], -0.16 to 3.10; P = 0.11 for noninferiority). Major or clinically relevant nonmajor bleeding had occurred in 33 patients (Kaplan-Meier estimate, 2.0%) in the monotherapy group and in 82 patients (Kaplan-Meier estimate, 4.9%) in the dual antiplatelet therapy group (absolute risk difference, -2.97 percentage points; 95% CI, -4.20 to -1.73). Stent thrombosis occurred in 12 patients in the monotherapy group and in 4 in the dual antiplatelet therapy group.
CONCLUSIONS: Among patients who had undergone successful PCI for acute coronary syndromes, potent P2Y12 inhibitor monotherapy was not found to be noninferior to dual antiplatelet therapy with respect to a composite of death or ischemic events at 12 months. (Funded by the Brazilian Ministry of Health; NEO-MINDSET ClinicalTrials.gov number, NCT04360720.).
参考来源
- Guimarães PO, Franken M, Tavares CAM, et al. Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes. N Engl J Med. 2025. PMID: 40888723. doi:10.1056/NEJMoa2507980
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。